Validated using a knockout cell line
Recombinant
RabMAb

Anti-BRCC36 antibody [EPR4365] (ab108295)

Overview

  • Product name
    Anti-BRCC36 antibody [EPR4365]
    See all BRCC36 primary antibodies
  • Description
    Rabbit monoclonal [EPR4365] to BRCC36
  • Tested applications
    Suitable for: WB, IP, ICCmore details
    Unsuitable for: Flow Cyt or IHC-P
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide corresponding to residues in Human BRCC36.

  • Positive control
    • HAP1, MCF7, SKBR3, 293T, Human fetal kidney and HeLa cell lysates.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab108295 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 36 kDa.
IP 1/10 - 1/100.
ICC 1/50 - 1/100.
  • Application notes
    Is unsuitable for Flow Cyt or IHC-P.
  • Target

    • Function
      Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:20656690, PubMed:24075985, PubMed:26344097, PubMed:26195665). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985, PubMed:26344097). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985).
    • Tissue specificity
      Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Aberrantly expressed in the vast majority of breast tumors.
    • Involvement in disease
      A chromosomal aberration involving BRCC3 is a cause of pro-lymphocytic T-cell leukemia (T-PLL). Translocation t(X;14)(q28;q11) with TCRA.
    • Sequence similarities
      Belongs to the peptidase M67A family. BRCC36 subfamily.
      Contains 1 MPN (JAB/Mov34) domain.
    • Cellular localization
      Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. Localizes at sites of DNA damage at double-strand breaks (DSBs) (PubMed:20656690, PubMed:26344097). Interaction with FAM175B/ABRO1 retains BRCC3 in the cytoplasm (PubMed:20656690).
    • Information by UniProt
    • Database links
    • Alternative names
      • BRCA1-A complex subunit BRCC36 antibody
      • BRCA1/BRCA2 containing complex subunit 3 antibody
      • BRCA1/BRCA2 containing complex subunit 36 antibody
      • BRCA1/BRCA2-containing complex subunit 3 antibody
      • BRCA1/BRCA2-containing complex subunit 36 antibody
      • Brcc3 antibody
      • BRCC3_HUMAN antibody
      • BRCC36 antibody
      • BRISC complex subunit BRCC36 antibody
      • C6.1A antibody
      • Chromosome X open reading frame 53 antibody
      • CXorf53 antibody
      • Lys-63-specific deubiquitinase BRCC36 antibody
      • OTTHUMP00000061450 antibody
      see all

    Images



    • Predicted band size : 36 kDa

      Lane 1: Wild type HAP1 whole cell lysate (40 µg)
      Lane 2: Empty Lane
      Lane 3: BRCC36 knockout  HAP1 whole cell lysate (40 µg)
      Lane 4: MCF7 whole cell lysate (40 µg) 

      Lanes 1 - 4: Merged signal (red and green). Green - ab108295 observed at 36 kDa. Red - loading control, ab18058, observed at 130 kDa.

      ab108295 was shown to recognize empty when empty knockout samples were used, along with additional cross-reactive bands. Wild-type and empty knockout samples were subjected to SDS-PAGE.  Ab108295 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

    • All lanes : Anti-BRCC36 antibody [EPR4365] (ab108295) at 1/1000 dilution

      Lane 1 : MCF7 cell lysate
      Lane 2 : SKBR3 cell lysate
      Lane 3 : 293T cell lysate
      Lane 4 : Human fetal kidney lysate
      Lane 5 : HeLa cell lysate

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 36 kDa

    References

    ab108295 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab108295.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up